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Abstract
Purpose To prospectively evaluate the incidence of post-
ablation syndrome (fever and flu-like symptoms) and
impact on the quality of life in the first 10 days following
percutaneous image-guided cryoablation for renal cell
carcinoma (RCC).
Materials and Methods A prospective study of all
cryoablation procedures with biopsy proven RCC was
conducted with institutional review board approval
between 08/2012 and 04/2016. Sixty-four patients (43
males and 21 females) underwent cryoablation. Mean age
was 68 (range 24–86). A telephone questionnaire survey
was conducted on days 1, 3, 5, 7 and 10 following
cryoablation, and complications were recorded. Data col-
lected included temperature, degree of flu-like symptoms,
severity of pain, percentage of pain relief with analgesics,
interference with general activity and with work (graded on
a 0–10 Numeric Intensity Scale).
Results Following cryoablation, six patients (9%) out of 64
developed post-ablation syndrome. Thirty-three patients
(52%) developed flu-like symptoms only, which com-
pletely resolved by day 10 in 25 patients (39%). One
patient had pyrexia only, which was self- limiting by day
10. Twenty-four patients (38%) were asymptomatic. Pain
(mean score = 2.1) and interference on general activities
(mean score = 1.8) and work (mean score = 2) following
cryoablation peaked on day 3 and improved subsequently.
Forty-six patients (72%) had 90–100% pain relief by day
10. No major complications were observed.
Conclusion The full spectrum of post-ablation syndrome
following cryoablation occurs in approximately 9% of
patients; however, 61% of patients experience flu-like
symptoms in the first 10 days, which are self-limiting.
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Introduction
Over the last decade, percutaneous image-guided thermal
ablation has emerged as a useful minimally invasive
nephron-sparing therapeutic intervention to treat small
cancers in a variety of organs, in particular the liver and
kidney, where ablative techniques are now established
[1–4].
The two principal methods of thermal ablation are using
heat-based energy, e.g., radiofrequency ablation (RFA) or
microwave ablation (MWA) and cryoablation, which is an
ice-based energy to induce tissue necrosis and cancer cell
death [1, 5]. Image-guided [6] cryoablation utilises rapid
cooling of cryoprobes—small diameter (13–17 gauge)
straight metallic shafts, within targeted lesions to cause cell
necrosis by direct cellular injury and indirectly through
changes in the cellular microenvironment [7]. Cryoablation
has become favourable amongst clinicians, particularly for
the treatment of patients with impaired renal function or
with a solitary kidney [1, 8, 9].
For liver and kidney tumours, cryoablation has been
shown to be safe and efficacious through data generated
from cohort studies [10–14]. An important advantage of
cryoablation over RFA is the excellent visualisation of the
iceball on intraprocedural imaging such as computed
tomography (CT) or magnetic resonance imaging (MRI).
The size of the iceball correlates to tissue injury therefore
cryoablation offers accurate monitoring of the extent of
tissue damage and treatment margins to ensure adequate
tumour coverage [12]. Recent data suggest that in the
intermediate term, outcomes might be comparable to par-
tial nephrectomy, which is still seen as the gold standard
for small renal cancers (\ 4 cm) [15].
Initial clinical experience of the technique shows,
however, that some patients develop flu-like symptoms
similar to the post-ablation syndrome described following
RFA [16, 17] and post-embolisation syndrome seen in
patients who have undergone pre-operative embolisation of
liver or renal tumours [18–22].
This consists of low-grade fever, malaise, myalgia and
nausea or vomiting, which occurs typically in the first
24–48 h after the procedure. The mechanism for this
reaction has been speculated to stem from the production of
cytokines as part of an inflammatory response to the
necrotic tissues [6, 23, 24].
To our knowledge, there has not been any published
data evaluating post-cryoablation syndrome in a large
cohort of patients following cryoablation of renal cell
cancer (RCC).
The primary aim of this study was to evaluate
prospectively the incidence of post-cryoablation syndrome
and to determine its impact on the quality of life in the first
10 days after cryoablation.
Methods
Study Design
This prospective study of all image-guided renal cryoab-
lations in a single specialist oncology centre in the United
Kingdom was conducted with institutional review board
approval between August 2012 and April 2016. No ethics
approval was required as the study was not classified as
research under the United Kingdom National Health Ser-
vice Health Research Authority. All patients were followed
up with a standardised questionnaire to assess clinical
response.
Only patients treated with cryoablation for biopsy
proved RCC were included in the study cohort. Lesions
that were not biopsied or benign histological findings were
excluded from the study. Other exclusion criteria included
previous locoregional therapy to the kidney. All procedures
performed accordance with the ethical standards of the
institutional and/or national research committee and with
the 1964 Helsinki Declaration and its later amendments or
comparable ethical standards. Informed consent was
obtained for this survey in all cases by the interventional
oncology programme coordinator and nurse.
Cryoablation Pathway
All patients were recommended for cryoablation following
multidisciplinary team (MDT) assessment and consensus
agreement. The procedure was performed using a dedicated
computed tomography (CT)-equipped interventional suite
under general anaesthesia by a consultant interventional
radiologist (TMW or JTS). Contrast-enhanced CT guid-
ance allowed perioperative visualisation of the tumour and
its margin through sequential scanning. All patients were
scanned on a 64 slice MDCT scanner (Somatom Sensation
64, Siemens, Erlangen, Germany). For all scans, the tube
kilovoltage (kVp) was fixed at 120 kV and was not
adjusted according to patient size. Prior to insertion of the
cryoprobes, three helical acquisitions were performed. The
first was a non-contrast-enhanced scan, followed by arterial
and portal venous phase acquisitions which were per-
formed at 30 and 65 s, respectively, after injection of 100
mls of Niopam 300 intra-venous contrast agent (Bracco,
Milan, Italy). This was to confirm the tumour volume based
on the pre-procedural planning CT and determine the
number of cryoprobes required for treatment. Adjunctive
protective measures, including hydrodissection, pneumo-
dissection or retrograde pyeloperfusion, were taken to
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prevent injury to surrounding structures. The technique for
these has been described in a previous paper by Wah et al.
[25].
A combination of 17G Ice Sphere and Ice Seed cry-
oprobes (Galil Medical, Arden Hills, MN, USA) were
inserted percutaneously into the tumour under CT guid-
ance, typically at the periphery, simulating a clock-face
approach to sculpt the required ice ball to ensure an ade-
quate zone of ablation and effective coverage of the tumour
during treatment. Two complete cycles of freezing and
thawing were performed (typically a 10 min freeze fol-
lowed by 6 min thaw, then a 10 min freeze and 6 min
thaw). One or several needle biopsies were obtained for
histological confirmation immediate prior to cryoablation
treatment.
After cryoablation, all patients were monitored in the
post-general anaesthesia (GA) recovery area and vital
observations such as blood pressure, heart rate, oxygen
saturations and respiratory rate were monitored. Patients
were discharged home the next day if they were haemo-
dynamically stable and had recovered from GA to the point
of tolerating oral intake and were passing adequate vol-
umes of urine with stable renal function. Simple analgesia,
such as orally taken paracetamol and codeine, was pro-
vided if required in the post-operative period.
Post-cryoablation complications were classified based
on the Society of Interventional Radiology Classification
System into minor and major complications [26]. Minor
complications were defined as those of no clinical conse-
quence or requiring none or minimal conservative therapy
such as simple analgesia. Major complications included
those, which affected clinical consequence requiring fur-
ther therapy, hospitalisation, increase in level of care,
permanent adverse sequelae or death.
Clinical Response Survey After Cryoablation
A survey was conducted with a standardised questionnaire
on days 1, 3, 5, 7 and 10 following their cryoablation
procedure. Please see appendix section for the question-
naire. All inpatients and outpatients were surveyed with the
same questionnaire. This survey was conducted by one of
two interventional nurse/coordinators and carried out by
telephone if the patient had been discharged or in person if
the patient was still in hospital.
All patients were asked to monitor their temperatures in
the morning when they first woke up and as needed, for the
initial 10 days following their cryoablation. The patients
were instructed to use a forehead thermometer for tem-
perature measurements, which was given to them at
discharge.
Clinical symptoms including temperature, flu-like
symptoms, severity of pain, percentage pain relief with oral
analgesics, type of oral analgesic, and any interference with
general activity or work were recorded. All symptoms and
interferences with lifestyle were graded 0–10 with a
numeric intensity scale. Fever was defined as
temperature[ 37 C.
Post-ablation Syndrome
A full complete spectrum of post-ablation syndrome is
defined as a combination of fever and flu-like symptoms,
which includes myalgia, malaise and pain at the site of
ablation. This is similar to the recognised post-embolisa-
tion syndrome and post-ablation syndrome following RFA,
which has been defined in the literature [9, 16, 17, 19, 21].
Statistical Analysis
Statistical analysis was performed with software (Minitab
Express, State College, Pennsylvania, USA). Patients with
post-ablation syndrome, the presence of either fever or flu-
like symptoms or both were compared using a two-sample
t test to assess whether the presence of fever influenced the
severity/grade of the flu-like symptoms.
Simple linear regression analysis was used to see if there
was any correlation between cryoablation time and severity
of flu-like symptoms and pain. Analysis of variance was
used to compare the number of cryoprobes with the
severity of flu-like symptoms and post-procedure pain
experienced to see if there was any correlation.
Results
A total of 64 patients underwent cryoablation for biopsy
proven RCC and met the inclusion criteria. Of these, 43
patients were male and 21 were female, with a mean age of
68 (range 24–86). One patient had two renal tumours
cryoablated; therefore, a total of 65 renal lesions histo-
logically confirmed as renal cell carcinoma (RCC) were
ablated. The pathology of the specimens was clear cell
RCC (n = 50); papillary type RCC (n = 8) and chromo-
phobe type RCC (n = 7). The average size of the ablated
renal lesion was 3.0 cm (range 0.9–6.8 cm). Mean CRYO
time was 34.5 min (range 31–51 min), and mean number
of cryoprobes used was 6 (range 2–12).
Three patients had adjunctive protective measures dur-
ing cryoablation: Two patients had hydro-pneumo-dissec-
tion and one patient had hydrodissection.
No patient experienced major complications following
cryoablation. Pain, fever and flu-like symptoms were the
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most common minor complications and will be discussed
in the following sections.
Post-ablation Syndrome
Seven patients (11%) in total developed a fever (tempera-
ture[ 37 C) in the first 10 days following cryoablation.
The mean temperature in the first 10 days following
cryoablation was 36.3 C (range 35–38.5). The mean
temperature of all patients who did not have fever com-
pared with those who had fever is shown in Fig. 1.
The mean temperature in the group with fever peaked on
day 3. A total of 39 patients (61%) experienced flu-like
symptoms following cryoablation, with the peak in severity
of symptoms on day 3. The mean score for flu-like
symptoms (out of 10) in the first 10 days following
cryoablation was 1.6 (range 0–8).
Six patients (9%) out of 64 developed complete post-
ablation syndrome and experienced both fever and flu-like
symptoms. These flu-like symptoms peaked on day 3 and
resolved spontaneously in 5 out of the 6 cases. In the case
where the flu-like symptoms did not resolve, the patient
had remained an inpatient following cryoablation and
developed their first pyrexial episode (temperature of
39 C) on day 10, which was attributed to a chest infection
and right foot cellulitis, which subsequently resolved with
antibiotics.
Thirty-three patients (52%) developed flu-like symp-
toms only, without fever during the first 10 days following
cryoablation. These flu-like symptoms had completely
resolved by day 10 in 25 of the 33 patients. Of the eight
patients who had residual flu-like symptoms on day 10, six
rated the severity as only 1 or 2.
One patient developed fever without any flu-like
symptoms. This resolved without any treatment by day 10.
Twenty-four patients (37.5%) did not have any flu-like
symptoms or fever following cryoablation.
The mean scores for flu-like symptoms in the first
10 days following cryoablation in patients who had com-
plete spectrum of post-ablation syndrome (n = 6) (fever
and flu-like symptoms) compared with the flu-like symp-
toms in patients who did not have fever (n = 33) shows
that the patients who had fever also experienced more
severe flu-like symptoms as demonstrated by a higher
mean score (Fig. 2), most marked on day 1 and 2. The
severity of symptoms peaked in both groups on day 3. This,
however, did not reach statistical significance following the
t test (P[ 0.05).
Pain and Lifestyle Interference
The mean pain severity score following cryoablation was
2.1 (range 0–8) over the 10 days. Eight patients (13%) had
no pain in the 10 days following cryoablation and 56
patients (87%) experienced some pain during the first
10 days, with the peak at day 3 where patients had a mean
score of 2.8 out of 10. Thirty-eight patients (59%) did not
require any analgesia for pain relief. Forty-six patients
(72%) had 90–100% relief of their pain by day 10 with or
without simple analgesics. Seventeen patients required
only simple orally taken paracetamol for pain relief, and
nine patients required orally taken ibuprofen or codeine in
addition to paracetamol. The overall percentage of pain
relief by day 10 with or without analgesics ranged from 0
to 100% (Mean = 8%).
Figure 3A shows the trend in mean pain experienced by
patients without fever (mean score at day 3 was 2.8) and
patients with fever (mean score at day 3 was 3.1)
(temperature[ 37 C).
Between day 1 and day 10, the mean interference on
general activities was 1.8 (range 0–10) and mean inter-
ference on work was 2.0 (range 0–10).
Fig. 1 Graph showing mean temperature (in degrees Celsius) in
patients after CRYO for renal lesion(s). To convert to Fahrenheit:
[F] = [C] 9 9/5 ? 32
Fig. 2 Graph showing the mean flu-like symptoms (0–10 numeric
grading scale) in the patients who experienced fever compared to the
mean flu-like symptoms in the patients who did not have fever
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The interference on general activities and work activi-
ties following cryoablation peaked on day 3 for both cat-
egories. The mean score for interference on general
activities at day 3 was 3.4, and the mean score for inter-
ference on work activities at day 3 was 3.2. Figure 3B, C
shows the mean interference on general activities and work
activities in the patients without fever and patients with
fever (temperature[ 37 C). For the patients who had
fever, there was a higher mean interference with general
activities and work compared to the group of patients
without fever; however, the trend was the same, with
improvement from day 3 onwards.
No statistical correlation was found between the total
cryoablation time or number of cryoprobes used with the
severity of the flu-like symptoms or pain experienced
(P[ 0.05).
Discussion
The primary thermal ablation techniques used for renal
tumours are RFA and cryoablation. At our institution, all
small renal tumours are treated with cryoablation. The
clear advantages of cryoablation over RFA are direct
visualisation of the ice ball under CT, allowing for precise
monitoring of the ablation zone [27]. Randomised control
trial data comparing RFA and cryoablation found in the
cryoablation group there was a significantly lower local
tumour progression rate, which could be due to better
visualisation of the treatment margins to optimise onco-
logical control [13]. CT guidance is preferred over ultra-
sound to allow for the exact anatomical relationship of the
cryoprobes with the tumour and surrounding organs to be
delineated in real-time. While CT allows for visualisation
of the entire ice ball, ultrasound has a limitation with its
inner margin, which is limited by acoustic shadowing.
Similarly, post-ablation complications such as bleeding are
better assessed on CT than ultrasound [28].
Post-ablation syndrome has been studied in more depth
for RFA. In one prospective study [16], one-third of
patients had the complete spectrum of post-ablation syn-
drome, with low-grade fever and flu-like symptoms (tem-
perature[ 37 C). There appears to be a lower incidence
of complete post-ablation syndrome following cryoablation
with only six patients (9%) having a complete post-ablation
syndrome.
However, the results for patients experiencing at least
one of the components of post-ablation syndrome are
similar for our cryoablation cohort compared to other
published data on RFA, which found 56% experienced
either fever or flu-like symptoms. In this study, 63%
developed either flu-like symptoms (n = 39) or fever
(n = 1). In a previous RFA study [16], a total of 42% of
patients developed a low-grade fever (between 37 and
39 C) compared to 11% in our cryoablation cohort. If the
main driver of fever was from the inflammatory response
secondary to the tissue death caused by the ablation one
would expect a similar proportion of patients undergoing
RFA and cryoablation to have fever, given the previous
study [16] had a mean renal tumour size of 3.1 cm and this
study had a mean tumour size of 3 cm. It is unclear as to
Fig. 3 Graph showing: AMean pain in the patients without fever and
patients with fever (temperature[ 37 C). B Mean interference with
general activity in the patients without fever and patients with fever
(temperature[ 37 C). CMean interference with work in the patients
without fever and patients with fever (temperature[ 37 C)
274 J. Zhong et al.: Incidence of Post-ablation Syndrome Following Image-Guided Percutaneous…
123
what may result in this discrepancy in the incidence of
post-cryoablation fever and it is unknown whether the
cooling effect from the cryoprobes during the procedure
reduces the effect from local inflammatory mediators
caused by the cell death. The mean temperature in the
cryoablation group with fever peaked on day 3 and self-
limiting following this, in the same trend as the fever
experienced following RFA [16].
Our data appears to suggest the presence of fever may
exacerbate the severity of flu-like symptoms that are
experienced with a higher mean grade of flu-like symptoms
especially on day 1 and 3 for patients with concomitant
fever. We acknowledge the data does not demonstrate
causation rather an association. This correlation was not
statistically significant on our t test; however, this is likely
due to the small sample of patients we had, particularly in
the fever group. Similarly, no significant statistical corre-
lation was found between the total cryoablation time and
the number of cryoprobes with flu-like symptoms or pain.
Theoretically, it would be expected that a larger volume of
ablated tissue would result in a greater inflammatory
response and therefore more severe post-ablation symp-
tomatology. The lack of statistical correlation may relate to
the sample size with only 18 patients (28%) where more
than 6 cryoprobes were used, of which six patients (9%)
required more than 10 cryoprobes.
It is vital to distinguish the clinical course of post-ab-
lation syndrome after cryoablation with post-procedural
complications such as concurrent infection. Overall, post-
cryoablation syndrome symptoms tend to be mild, with a
low-grade fever, and self-limiting and resolve sponta-
neously with conservative management compared to con-
current infection which should be considered in the event
of unresolving or delayed onset fever as seen in the patient
from our cohort who developed a concurrent chest infec-
tion and cellulitis.
The mean pain experienced in the first 10 days follow-
ing cryoablation is similar to published post-RFA results
and the cooling effect of cryoablation does not appear to
have a therapeutic effect on overall pain although overall
scores remain low (mean score 2.1) with 72% having
90–100% pain relief by day 10 with simple analgesics and
26 patients (41%) having no pain by day 10, without the
use of any analgesics. Quantification of pain and evaluation
of interference with lifestyle through effect on general
activities and work remains subjective. Our survey high-
lights a trend in the pain experienced following cryoabla-
tion that peaks on day 3, slightly later than the pain
following RFA, which peaked on day 1. The overall mean
scores are, however, comparable. There was also no sta-
tistically significant difference in the pain experienced with
or without concurrent fever.
The mean scores for interference on general activities
(mean score 1.8 out of 10) and work (mean score 2.0)
which both peaked on day 3 in our cryoablation group were
similar to the published RFA data, with fever having no
apparent influence on the severity of lifestyle interference.
In Wah et al. [16], the overall interference with general
activities was 5.2 and interference with work was 5.4;
however, this included both liver and renal RFA where the
patients with liver lesions experienced greater lifestyle
interference thereby skewing the mean results [16]. No
significant difference is noted in the lifestyle interference
following cryoablation from our data compared to post-
RFA published data.
This study is limited by its small sample size and sub-
jectivity from the patient’s own measurement of their
temperature and using a telephone survey to assess clinical
symptoms and lifestyle interference. It does form the basis
for a larger formal study to review such findings.
Conclusion
The full spectrum of post-ablation syndrome following
cryoablation occurs in approximately 9% of patients;
however, 61% of patients experience flu-like symptoms in
the first 10 days, which are self-limiting.
Patients should be reassured that such symptoms are
often self-limiting and further investigation is only required
when there is persistent or late onset fever indicating
possible concurrent infection.
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